bioRxivBiochemistryPreprint
Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses
S. N. Zvornicanin, A. M. Shaqra, Q. Y. Huang, E. Ornelas, M. Moghe, M. Knapp, S. Moquin, D. Dovala, C. A. Schiffer, N. Kurt Yilmaz
Abstract
With the spread of SARS-CoV-2 throughout the globe to cause the COVID-19 pandemic, the threat of zoonotic transmissions of coronaviruses (CoV) has become even more evident. As human infections have been caused by alpha- and beta-CoVs, structural characterization and inhibitor design mostly focused on these two genera. However, viruses from the delta and gamma genera also infect mammals and pose potential zoonotic transmission threat. Here, we determined the inhibitor-bound crystal structures of the main protease (Mpro) from the delta-CoV porcine HKU15 and gamma-CoV SW1 from beluga whale. Comparison with the apo structure of SW1 Mpro, which we also present here, enabled identifying structural arrangements upon inhibitor binding at the active site. The binding modes and interactions of two covalent inhibitors, PF-00835231 (lufotrelvir) bound to HKU15 and GC376 bound to SW1 Mpro, reveal features that may be leveraged to target diverse coronaviruses and toward structure-based design of pan-CoV inhibitors.
- organism: mouse
- organism: human
- assay: structural biology
- research focus: protein structure prediction
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structural basis of main proteases of coronavirus bound to drug candidate PF-07321332
- Structural basis for the inhibition of coronaviral main proteases by PF-00835231
Xuelan Zhou, Xiaolu Lu, … Jian Li·Acta Biochimica et Biophysica SinicaPeer-reviewed·Jul 29, 2024
- Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease
D. W. Kneller, G. Phillips, … A. Kovalevsky·bioRxiv·Jan 12, 2021
- Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L
M. D. Sacco, C. Ma, … J. Wang·Science AdvancesPeer-reviewed·Dec 11, 2020
- An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity
N. Kitamura, M. D. Sacco, … J. Wang·bioRxiv·Dec 19, 2020
- Conserved interactions required for in vitro inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
A. Shitrit, D. Zaidman, … O. Kobiler·bioRxiv·Sep 10, 2020